CSL offshoot Seqirus has confirmed the national availability of its Schedule 2 Nervoderm medicated nerve pain patch.
The over-the-counter medicine has been shown to provide 12-hour relief from nerve pain associated with medically diagnosed post-herpetic neuralgia (PHN).
"Pain associated with PHN can be debilitating and may be associated with a substantial impact on a patient's quality of life," said Dr Lorna Meldrum, VP Commercial Operations at Seqirus.
The clinically trialled product has already been available on a limited basis in Vic under a recent successful pilot program.
Meldrum said Seqirus had worked closely with its distribution partner, Pharmabroker Sales, on the pilot scheme, and would continue the collaboration to expand access to Nervoderm across Australia.
To support awareness of the national rollout, Seqirus will launch a major TV and radio campaign this month, including spots featured throughout the Australian Open Tennis tournament as well as free-to-air and pay TV channels.
See nervoderm.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Jan 19
